Doximity/$DOCS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Doximity
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
- Ticker
- $DOCS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 880
- Headquarters
- San Francisco, United States
- Website
- www.doximity.com
Doximity Metrics
BasicAdvanced
$5.9B
39.26
$0.84
1.21
-
Price and volume
Market cap
$5.9B
Beta
1.21
52-week high
$71.37
52-week low
$17.15
Average daily volume
3.1M
Financial strength
Current ratio
6.078
Quick ratio
5.796
Long term debt to equity
0.008
Total debt to equity
0.011
Profitability
EBITDA (TTM)
208.403
Gross margin (TTM)
88.07%
Net profit margin (TTM)
25.48%
Operating margin (TTM)
30.57%
Effective tax rate (TTM)
26.16%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
10.95%
Return on equity (TTM)
17.21%
Valuation
Price to earnings (TTM)
39.261
Price to revenue (TTM)
9.368
Price to book
6.49
Price to tangible book (TTM)
7.46
Price to free cash flow (TTM)
20.682
Free cash flow yield (TTM)
4.84%
Free cash flow per share (TTM)
1.599
Growth
Revenue change (TTM)
11.18%
Earnings per share change (TTM)
-27.94%
3-year revenue growth (CAGR)
14.49%
3-year earnings per share growth (CAGR)
14.56%
What the Analysts think about Doximity
Analyst ratings (Buy, Hold, Sell) for Doximity stock.
Analyst projections of the future price of Doximity stock.
Bulls say / Bears say
Workflow adoption is accelerating: active prescribers using Doximity’s tools grew more than 30% year on year, nearly half used its AI tools, and Scribe users rose tenfold in July. A larger, more engaged clinician base creates more room to grow workflow subscriptions and advertising. (Doximity, The Motley Fool)
AI Search is beginning to turn engagement into paid business: management said new contracts helped drive a $6 million increase to its fiscal 2027 revenue outlook. It expects a stronger contribution as larger customer contracts are signed. (The Motley Fool)
Doximity entered this investment cycle with substantial cash-generating capacity: fiscal 2026 free cash flow rose 19% to $317.5 million and adjusted EBITDA rose 14% to $357.8 million. That gives it resources to fund product development while remaining profitable. (Doximity)
The core pharma-advertising market is weak, with management citing policy and economic uncertainty, shorter customer commitments and limited visibility. It expected market growth of 5% or less and forecast only about 4% revenue growth at the midpoint for fiscal 2027. (The Motley Fool)
AI adoption is raising costs faster than profits: in the latest quarter adjusted EBITDA fell 6% year on year and free cash flow fell 34%, while non-GAAP gross margin slipped to 87.5% from 91.2%. Continued compute spending could weigh on returns if monetisation does not catch up. (Doximity, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
Doximity Financial Performance
Revenues and expenses
Doximity Earnings Performance
Company profitability
Upcoming events
No upcoming events
Doximity News
AllArticlesVideos
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
Newsfile Corp8 hours ago
ROSEN, A TOP-RANKED LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
Newsfile Corp1 day ago
Kaplan Fox Alerts Doximity, Inc. (DOCS) Investors to an Approaching Lead Plaintiff Deadline on November 16, 2026
Newsfile Corp2 days ago
Funds containing Doximity
AllUSDEURGBP
Fund name | Fund size | $DOCS weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.12% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.12% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.06% |
iShares MSCI World Small Cap£WLDS | $9B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.